Overview

Trial of Artesunate Combination Therapy in Pakistan

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study is an evaluation of the benefit of adding artesunate to existing first and second line antimalarial therapies in Pakistan. A placebo controlled trial was carried out to assess two potential benefits of Artesunate Combination Therapy (ACT): efficacy and potential for transmission reduction.
Phase:
Phase 2
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborator:
HealthNet TPO
Treatments:
Artemisinins
Artesunate
Chloroquine
Chloroquine diphosphate
Fanasil, pyrimethamine drug combination
Primaquine
Pyrimethamine
Sulfadoxine